Medherant: Difference between revisions
fix lead, add cats |
Nominated for deletion; see Wikipedia:Articles for deletion/Medherant. |
||
| Line 1: | Line 1: | ||
<!-- Please do not remove or change this AfD message until the discussion has been closed. --> | |||
{{Article for deletion/dated|page=Medherant|timestamp=20261004181308|year=2026|month=October|day=4|substed=yes|help=off}} | |||
<!-- Once discussion is closed, please place on talk page: {{Old AfD multi|page=Medherant|date=4 October 2026|result='''keep'''}} --> | |||
<!-- End of AfD message, feel free to edit beyond this point --> | |||
{{POV|date=August 2023}} | {{POV|date=August 2023}} | ||
{{Short description|British pharmaceutical company}} | {{Short description|British pharmaceutical company}} | ||
Revision as of 18:13, 4 October 2026
| This article is being considered for deletion in accordance with Wikipedia's deletion policy. Please share your thoughts on the matter at this article's entry on the Articles for deletion page. Feel free to edit the article, but the article must not be blanked, and this notice must not be removed, until the discussion is closed. For more information, particularly on merging or moving the article during the discussion, read the Guide to deletion. |
Template:POV Template:Short description Template:Use dmy dates Template:Use British English Template:Self-published
Medherant Ltd is a British pharmaceutical company, based in Coventry. The company is developing over-the-counter (OTC) and prescription transdermal patches for drug delivery.
History
Medherant Ltd was founded as a university spin-off by Professor David Haddleton and the University of Warwick in 2015 for the purpose of commercialisation of a novel drug delivery system. Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the University of Warwick Science Park since March 2015 after securing an investment from the Mercia Fund Management in 2014 and has received over £15M investment by the end of 2025.
Research
Using its research in polyurea based pressure sensitive adhesives[1] and polymer chemistry, the company is working to introduce transdermal drug delivery patches via the transepidermal route.[2] Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no solvents for the fabrication process.[3]
Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women[4] which has shown excellent results to date.[5] Medherant has also been developing transdermal analgesic patches for pain relief, based on nonsteroidal anti-inflammatory drugs (NSAIDs), e.g. ibuprofen, lidocaine, diclofenac and methyl salicylate.
References
- ↑ Efstathiou, Spyridon; Nurumbetov, Gabit; Ross, Andrew; Li, Yongguang; Haddleton, David M. (2024-04-22). "Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD)" (in en). Materials Advances 5 (8): 3396–3410. doi:. ISSN 2633-5409. https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f.
- ↑ "Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin". University of Warwick. https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/. Retrieved on 16 October 2016.
- ↑ "Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines". Medherant Ltd. http://www.medherant.co.uk/about-us. Retrieved on 16 October 2016.
- ↑ "Menopause testosterone patch to begin trials" (in en-GB). BBC News. 2023-04-03. https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981.
- ↑ "Medherant announces positive Phase 1 clinical trial results". https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results.